
As Vaxcyte’s products progress toward late-stage development and commercialization, the Manufacturing organization requires robust digital tools, structured project tracking, and disciplined readiness oversight to support commercial launch preparation and routine GMP manufacturing. This position will support the Manufacturing organization by developing, maintaining, and driving Smartsheet-based trackers, dashboards, action logs, and gap-assessment tools that enable clear visibility into commercial readiness, documentation status, manufacturing campaign preparation, risks, dependencies, and cross-functional deliverables.
Working closely across the Manufacturing team, MSAT, Process Development, Supply Chain, Quality, Regulatory, Project Management, Business Development, and multiple CDMOs/CMOs, this position will help establish structure, transparency, and governance across operational readiness activities. The role will be accountable for supporting readiness gap assessments, tracking closure of actions, consolidating input from stakeholders, monitoring document and campaign readiness, supporting organizational maturation, and preparing clear status updates for Manufacturing leadership. In addition, the role will provide direct support to the Head of Manufacturing with meeting administration, governance routines, team event coordination, and follow-up management. The ideal candidate will combine strong project tracking and digital tool capabilities, particularly Smartsheet, with an understanding of GMP manufacturing operations, commercial readiness, organizational effectiveness, and cross-functional collaboration in a biologics or vaccine manufacturing environment. This position will report to the Executive Director Manufacturing of Vaxcyte Switzerland.
Ideal Candidate Profile:
The ideal candidate is a highly structured manufacturing systems and operations enablement professional with experience in GMP biotech or pharma environments, preferably biologics, vaccines, or external manufacturing. This person does not need to be a deep technical manufacturing expert, but must understand manufacturing operations, documentation, campaign readiness, and CMO/CDMO interfaces well enough to create clarity, structure, visibility, and follow-through across complex cross-functional work.
The strongest candidate will be highly skilled in Smartsheet and digital project tracking, able to build dashboards, trackers, action logs, readiness heatmaps, and reporting tools that translate complex information into clear management visibility. They will serve as an operational backbone for the Manufacturing organization by bringing digital discipline, governance, operating rhythm, meeting discipline, and proactive support to the Head of Manufacturing while helping the function mature its systems, routines, and ways of working.
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.